Drugs / MFA-370
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05390645 | Dec 2024 → Dec 2025 | urothelial carcinoma | Ectin Research AB | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MFA-370 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05390645 ↗ |
| Route | Oral | “MFA-370 is taken orally once daily for up to 24 weeks.” NCT05390645 ↗ |